CSE: BUX | OTCQB: BMKDF | FSE: 20B
Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) an advanced-stage liquid biopsy company with a
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia – (December 29th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE:
BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid A Bux | CEO and Founder | BioMark Diagnostics Inc
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY Vancouver, British Columbia – (December 4th, 2023) – BioMark
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM Vancouver, British Columbia – (November 28th, 2023) – BioMark Diagnostics Inc. (“BioMark”
BIOMARK STRENGTHENS AND EXPANDS ITS STRATEGIC ADVISORY TEAM IN PURSUIT OF COMMERCIALIZATION INITIATIVES Dr. W. Randolph Ford, Ph.D., will be joining BioMark’s Advisory team to
BIOMARK ANNOUNCES FINANCIAL CONTRIBUTION FROM THE CITY OF QUEBEC TO SUPPORT COMMERCIALIZATION INITIATIVES OF ITS PROPRIETARY LUNG CANCER DETECTION TEST Vancouver, British Columbia and Québec
BIOMARK TO UNVEIL RESULTS OF ITS EARLY BREAST CANCER STUDY AT THE UPCOMING SAN ANTONIO BREAST CANCER SYMPOSIUM Analyses from a retrospective study of early
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis This article recently appeared in the French-Canadian
